5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityArterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorderRecruitingPhase 32026-10-08NCT07037433
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionFamilial Primary Pulmonary Hypertension, Skin and Connective Tissue Diseases, cardiovascular disorder, connective tissue disorder, hypertensive disorder, lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder, vascular disorderEnrolling by invitationPhase 32026-10-06NCT03683186
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes TrialArterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorderActive, not recruitingPhase 32026-02-27NCT05581303
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitisActive, not recruitingNot stated2025-12-24NCT05817942
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial SpondyloarthritisAxial Spondyloarthritis, Spondylarthritis, Spondylarthropathies, ankylosis, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, spondylitis, vertebral column disorderActive, not recruitingPhase 32025-12-04NCT05785611